| Business Summary | | Myriad
Genetics,
Inc.
engages
in
the
use
of
gene-based
medicine
to
develop
novel
therapeutic
and
molecular
diagnostic
products.
The
Company
focuses
on
the
emerging
field
of
proteomics,
which
involves
establishing
the
relationship
between
protein
function
and
particular
diseases
by
identifying
disease-specific
proteins.
Myriad
employs
a
variety
of
proprietary
proteomic
technologies
to
discover
important
disease
genes
and
to
understand
the
role
these
genes
and
their
related
proteins
play
in
the
onset
and
progression
of
disease.
Using
proprietary
technologies,
the
Company
identified
22
drug
targets
to
date.
Myriad
delivered
13
of
these
drug
targets
to
its
strategic
partners
based
on
its
discovery
of
genes
involved
in
breast
cancer,
brain
cancer,
prostate
cancer,
heart
disease,
dementia
and
other
disorders.
Partners
include
Bayer
Corporation,
Eli
Lilly
and
Company,
Hitachi
Ltd.,
Hoffmann-LaRoche
Inc.,
Pharmacia
Corporation,
Novartis
Corporation,
Schering-Plough
Corporation
and
Schering
AG. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | MYGN
is
engaged
in
the
discovery
and
sequencing
of
genes
related
to
major
common
diseases.
MYGN
operates
a
genetic
predisposition
testing
lab
and
develops
products
to
prevent
or
treat
the
diseases
associated
with
these
genes.
For
the
nine
months
ended
3/31/01,
revenues
increased
38%
to
$34.3
million.
Net
loss
fell
19%
to
$5
million.
Revenues
reflect
increased
research
revenue
from
strategic
alliances.
Lower
loss
benefitted
from
increased
interest
income. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
10,822;
after
tax
earnings
were
-2,187. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Hugh D'Andrade Chairman | -- | -- | Peter Meldrum, 53 Pres,
CEO, | $426K | $5.8M | Walter Gilbert, Ph.D., 68 Vice
Chairman | -- | -- | Jay Moyes, 46 CFO
and VP of Fin. | 234K | 1.8M | Gregory Critchfield, M.D., 49 Pres
of Myriad Genetic Laboratories, Inc. | 330K | 1.3M | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|